What BridgeBio Pharma (BBIO) said on its Q3 earnings call. BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's commercialization of Beyonttra. The company also outlined plans for three potential U.S. product launches over the next seven months, subject to Food and Drug Administration decisions. Total revenue for the third quarter of 2026 was $353.2 million, compared with $120.7 million a year earlier. U.S. Attruby net product revenue reached $253.2 million, up 14% sequentially and 134% year over year. Revenue also included a $75 million one-time Beyonttra sales milestone from Bayer and $20.5 million in royalty revenue, primarily from Beyonttra sales in Europe and Japan. President and Chief Financial Officer Tom Trimarchi said the company recorded an operating loss of $11.6 million, improving from a $145.2 million operating loss in the prior-year quarter. Operating expenses rose to $344.4 million from $259.3 million as BridgeBio invested in Attruby and prepared for upcoming launches. As of Sept. 30, BridgeBio held $1.5 billion in cash, cash equivalents and marketable securities, which Trimarchi described as the company's strongest reported cash position. He said the company expects operating expenses to increase in the fourth quarter as launch-related spending catches up, followed by more modest expense growth and improving operating results through 2027. Attruby growth and real-world evidence. Chief Executive Officer Neil Kumar said BridgeBio's Attruby/Beyonttra franchise is annualizing at more than $1 billion in the U.S. market and above that level globally. He reiterated the company's belief that the franchise can meet or exceed its $4 billion peak-sales assumption. Kumar said growth in the U.S. is increasingly being driven by first-line patient starts. BridgeBio has seen Attruby prescribed by roughly 2,900 physicians, largely cardiologists at academic medical centers and high-volume heart-failure practices. He said more than 60% of potential prescribers have yet to try the product, with many of those clinicians being lower-volume or non-cardiology specialists. During the question-and-answer session, Chief Business Officer Chinmay Shukla said a quarterly Attruby revenue increase of roughly $25 million to $30 million is the appropriate near-term expectation, with potential for that figure to rise over time. Chief Commercial Officer Matt Outten said persistency, compliance and gross-to-net trends have remained stable, while the number of physicians initiating Attruby in the first-line setting continues to expand. Management highlighted two recent comparative real-world analyses of acoramidis, the active ingredient in Attruby, versus tafamidis. Kumar said a study using Komodo U.S. claims data found acoramidis was associated with a 34% reduction in composite clinical worsening and a 43% reduction in diuretic intensification compared with tafamidis. Separately, an analysis presented at the Heart Failure Society of America meeting using Epic Cosmos electronic health record data associated acoramidis with lower risks of a composite of death, hospitalization, new-onset atrial fibrillation and diuretic intensification. BridgeBio also said Bayer's Beyonttra launch has been strong in Europe, where Kumar said the brand is the market leader. The company received the $75 million sales milestone earlier than it had expected. Three regulatory decisions ahead. BridgeBio expects FDA decisions on three programs in the coming months: * BBP-418 for limb-girdle muscular dystrophy type 2I/R9: PDUFA date of Nov. 27, 2026. The company said no advisory committee meeting is planned. If approved, it would be the first therapy for any limb-girdle muscular dystrophy. * Infigratinib for achondroplasia: Priority-review PDUFA date of Feb. 4, 2027. BridgeBio has also submitted a European marketing application and expects a potential European decision in the second half of 2027. * Encaleret for autosomal dominant hypocalcemia type 1, or ADH1: Priority-review PDUFA date of May 8, 2027. No advisory committee is planned, according to the company. For BBP-418, BridgeBio said it has identified more than 500 genetically diagnosed U.S. patients and that about 70% receive care through the Muscular Dystrophy Association Care Center Network. Anna Wade, chief operating officer of BridgeBio Neuromuscular, said the company expects its account managers to reach more than 90% of those centers by the PDUFA date. She said BridgeBio's discussions with FDA have remained positive and that management expects a traditional full approval rather than accelerated approval. BridgeBio plans to submit a European marketing authorization application for BBP-418 in the first half of 2028, based on final 36-month FORTIFY trial data expected in late 2027 or early 2028. Wade said European health authorities requested the longer-term data, and BridgeBio estimates there are more than 4,000 patients in Europe with the condition. Pipeline expansion and launch preparations. For infigratinib, management said the FDA granted priority review for the achondroplasia application. The company said its commercial field team is staffed and has been conducting disease-state education. Justin To, chief executive of BridgeBio Skeletal Dysplasias, said the company does not expect a citizen petition from competitor Ascendis to affect the FDA review timeline or potential label. For encaleret, BridgeBio said it has identified more than 600 genetically confirmed ADH1 patients in the U.S., up from about 500 in the previous quarter. The company is also expanding the drug's development into chronic hypoparathyroidism. It dosed the first participant in the global Phase III RECLAIM-HP study in October. The RECLAIM-HP study is expected to enroll approximately 160 patients and evaluates the proportion of participants achieving normal blood and urine calcium at week 24. Ananth Sridhar, chief operating officer of BridgeBio Cardiorenal, said BridgeBio estimates the chronic hypoparathyroidism population at roughly 200,000 people in the U.S. and Europe, compared with about 25,000 people with ADH1 in those markets. The company anticipates top-line results from RECLAIM-HP within 15 months. Kumar also said BridgeBio nominated BBP-717, a next-generation monoclonal antibody program for ATTR cardiomyopathy, as a development candidate. The company plans to file an investigational new drug application for the program in 2027. About BridgeBio Pharma (NASDAQ:BBIO). BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes. BridgeBio's portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.

BridgeBio Pharma, Inc. $BBIO stock: China Universal Asset Management Co. Ltd. boosts position. October 30, 2026 Key points. * China Universal Asset Management increased its BridgeBio Pharma stake by 57% in the third quarter, bringing its holdings to 48,926 shares valued at approximately $3.23 million. * BridgeBio reported strong third-quarter results, with revenue rising 192.6% year over year to $353.2 million and a loss of $0.42 per share, better than analysts' expectations. Attruby revenue reached $253.2 million, while the company ended the quarter with $1.5 billion in cash and marketable securities. * Institutional investors own 99.85% of BBIO, and analysts maintain a "Moderate Buy" consensus with an average price target of $104.63, although the company remains unprofitable and execution of its product launches remains a key risk. * MarketBeat previews top five stocks to own in November. China Universal Asset Management Co. Ltd. boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 57.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,926 shares of the company's stock after acquiring an additional 17,755 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in BridgeBio Pharma were worth $3,228,000 as of its most recent filing with the SEC. A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BBIO. Silvant Capital Management LLC purchased a new stake in shares of BridgeBio Pharma during the 2nd quarter worth approximately $28,000. Allworth Financial LP bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $31,000. Root Financial Partners LLC purchased a new position in BridgeBio Pharma in the third quarter valued at approximately $28,000. SBI Securities Co. Ltd. lifted its stake in BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company's stock valued at $29,000 after purchasing an additional 157 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in BridgeBio Pharma in the second quarter valued at approximately $44,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors. BridgeBio Pharma news summary. Here are the key news stories impacting BridgeBio Pharma this week: * Third-quarter revenue reached $353.2 million, well above the approximately $293.5 million consensus estimate and up 192.6% year over year. * The company reported a quarterly loss of $0.42 per share, narrower than the $0.54 analyst consensus and significantly improved from a $0.95 loss in the year-earlier period. * U.S. Attruby net product revenue was $253.2 million, increasing approximately $31 million sequentially and $145 million year over year. The results reinforce the commercial momentum of BridgeBio's primary revenue-generating product. * BridgeBio ended September with $1.5 billion in cash, cash equivalents and marketable securities, which management said fully funds its three launches and expansion indications. This reduces near-term financing and dilution concerns. * Operating loss was $11.6 million, helped by higher revenue and a one-time $75 million BEYONTTRA sales milestone from Bayer. Investors may therefore distinguish recurring product growth from milestone-related revenue when assessing future quarters. * Despite the improvement, BBIO remains unprofitable, and the company's ability to sustain Attruby growth and execute its multiple launches will remain important to the stock's valuation. BridgeBio Pharma price performance. Shares of BBIO opened at $70.73 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $60.22 and a 52-week high of $93.42. The stock's 50-day simple moving average is $70.43 and its 200 day simple moving average is $72.85. Discover more MarketBeat All Access MarketBeat Research Tools BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million for the quarter, compared to analysts' expectations of $293.47 million. During the same period in the previous year, the firm earned ($0.95) EPS. The firm's quarterly revenue was up 192.6% compared to the same quarter last year. Sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.65 earnings per share for the current year. Insider activity at BridgeBio Pharma. In related news, CEO Neil Kumar sold 34,980 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the completion of the transaction, the chief executive officer owned 243,327 shares of the company's stock, valued at approximately $20,081,777.31. The trade was a 12.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 54,980 shares of company stock valued at $4,417,999 in the last three months. 14.23% of the stock is currently owned by company insiders. Wall Street analysts forecast growth. Several research analysts have recently weighed in on the company. Weiss Ratings downgraded BridgeBio Pharma from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, September 25th. Truist Financial boosted their price objective on BridgeBio Pharma from $102.00 to $107.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. UBS Group started coverage on shares of BridgeBio Pharma in a report on Thursday, October 15th. They set a "buy" rating and a $92.00 price objective on the stock. Wells Fargo & Company upped their price objective on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. Finally, Morgan Stanley cut their target price on shares of BridgeBio Pharma from $97.00 to $87.00 and set an "overweight" rating for the company in a research report on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BridgeBio Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.63. BridgeBio Pharma profile. BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes. BridgeBio's portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms. Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider BridgeBio Pharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list. While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat